Clinical efficacy of first‐line treatment of atelizumab plus bevacizumab for recurrent hepato‐cellular carcinoma after operationJ. Chinese Journal of Digestive Surgery, 2021, 20(102): 5-9. DOI: 10.3760/cma.j.cn115610-20211105-00544
Citation: Clinical efficacy of first‐line treatment of atelizumab plus bevacizumab for recurrent hepato‐cellular carcinoma after operationJ. Chinese Journal of Digestive Surgery, 2021, 20(102): 5-9. DOI: 10.3760/cma.j.cn115610-20211105-00544
shu

Clinical efficacy of first‐line treatment of atelizumab plus bevacizumab for recurrent hepato‐ cellular carcinoma after operation

    Graphical Abstract
    • Abstract
    • FullText(HTML)
  • loading
    • References (0)
    • Related Articles

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return